BioSpace News Archive

Cardinal Health announced that it is sending an irrevocable notice of early redemption to the holders of the Company’s $500 million 4.625% notes due 2020.

Solid Biosciences Inc. announced that, due to the public health impact of the novel coronavirus outbreak and governmental restrictions limiting the number of people who may gather together, its 2020 Annual Meeting of Stockholders, to be held on Tuesday, June 16, 2020 at 8:00 a.m.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies Virtual Healthcare Conference. The presentation will take place on Tuesday June 2, 2020 at 4:30PM ET. This meeting is being held virtually, and a live we

Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020. First Quarter 2020 Highlights Net Revenues for the first quarter of 2020 decreased to $7.4 million compared to $13.1 million in the same quarter of the prior year. The $5.7 million decrease was driven primarily by a $3.8 million decrease in US Teligent label products relat

Chicagoans, joined by friends from across the country and around the world, have sent a clear message: cancer hasn’t stopped, and neither will we. The 2020 Digital Discovery Ball, the American Cancer Society’s first-ever, large-s

CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has raised $15 million in a Series C financing round. The round was led by Valence Life Sciences, L

Recruitment of internationally recognized clinical, business, and commercialization experts’ bolsters company’s strategy and growth plans

Daiichi Sankyo Initiates Clinical Trial with 5 th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) GIST is a rare cancer of the digestive tract with limited treatment options available to patients who progress on standard TKI therapy DS-6157 is the fifth DXd ADC from the oncology pip

Genesis HealthCare (NYSE:GEN) (Genesis or the Company), one of the nation’s largest providers of post-acute care, today announced that it expects to release its first quarter ended March 31, 2020 results before the market opens on Wednesday, May 27, 2020. A conference call and webcast will be held on Wednesday, May 27, 2020 at 8:30 a.m. Eastern Time to discuss the results. To participate in the call, interested parties may dial (855) 849-21